Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28040384 | 0.81 | RAPGEF4 (0.36) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL10319941 | 0.79 | RAPGEF4 (0.35) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL28951 | 0.75 | RAPGEF4 (0.59) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL1551822 | 0.75 | RAPGEF4 (0.59) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL10318045 | 0.74 | — | — | |
| SCHEMBL28482658 | 0.72 | RAPGEF4 (0.56) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL5180888 | 0.72 | RAPGEF4 (0.56) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL10412763 | 0.72 | RAPGEF4 (0.56) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL6255294 | 0.69 | RAPGEF4 (0.53) | RAPGEF4ACHEALDH1A1KDM4ELMNA | |
| SCHEMBL30448595 | 0.67 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919300-B2 | 1-hexene production process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2484685-B1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2484685-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | Sumitomo Chemical Co., Ltd (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | AP1M1, HK1, CYC1 | RAPGEF4 3868/4885ACHE 1223/4885ALDH1A1 1321/4885 |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | AP1M1, AP3M1, EMC1 | RAPGEF4 3504/4885ACHE 1522/4885ALDH1A1 2292/4885 |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | AP1M1, AMY1A, AP3M1 | RAPGEF4 2624/4885ACHE 275/4885ALDH1A1 2399/4885 |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | EMC1, CYC1, AP1M1 | RAPGEF4 3408/4885ACHE 962/4885ALDH1A1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.